Your browser doesn't support javascript.
loading
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson's Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD Trial.
Peterschmitt, M Judith; Saiki, Hidemoto; Hatano, Taku; Gasser, Thomas; Isaacson, Stuart H; Gaemers, Sebastiaan J M; Minini, Pascal; Saubadu, Stéphane; Sharma, Jyoti; Walbillic, Samantha; Alcalay, Roy N; Cutter, Gary; Hattori, Nobutaka; Höglinger, Günter U; Marek, Kenneth; Schapira, Anthony H V; Scherzer, Clemens R; Simuni, Tanya; Giladi, Nir; Sardi, Sergio Pablo; Fischer, Tanya Z.
Afiliação
  • Peterschmitt MJ; Sanofi, Cambridge, MA, USA.
  • Saiki H; Kitano Hospital, The Tazuke Kofukai Medical Research Institute, Osaka, Japan.
  • Hatano T; Juntendo University, Tokyo, Japan.
  • Gasser T; Neurologische Universitätsklinik, Tübingen, Germany; German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.
  • Isaacson SH; Parkinson's Disease and Movement Disorders Center, Boca Raton, FL, USA.
  • Gaemers SJM; Sanofi Genzyme, Amsterdam, Netherlands.
  • Minini P; Sanofi, Chilly-Mazarin, France.
  • Saubadu S; Sanofi, Chilly-Mazarin, France.
  • Sharma J; Sanofi, Bridgewater, NJ, USA.
  • Walbillic S; Sanofi, Chilly-Mazarin, France.
  • Alcalay RN; Department of Neurology and the Taub Institute, Columbia University Medical Center, New York, NY, USA.
  • Cutter G; University of Alabama at Birmingham, School of Public Health, Birmingham, AL, USA.
  • Hattori N; Juntendo University, Tokyo, Japan.
  • Höglinger GU; German Center for Neurodegenerative Diseases (DZNE), Munich, and Department of Neurology, Klinikum Rechts der Isar, Technical University Munich, Munich, Germany.
  • Marek K; Department of Neurology, Hannover Medical School, Hannover, Germany.
  • Schapira AHV; Institute for Neurodegenerative Disorders, New Haven, CT, USA.
  • Scherzer CR; Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London, London, UK.
  • Simuni T; Harvard Medical School and Brigham & Women's Hospital, Boston, MA, USA.
  • Giladi N; Northwestern University, Chicago, IL, USA.
  • Sardi SP; Neurological Institute, Tel Aviv Medical Center, Sackler School of Medicine, Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel.
  • Fischer TZ; Sanofi, Cambridge, MA, USA.
J Parkinsons Dis ; 12(2): 557-570, 2022.
Article em En | MEDLINE | ID: mdl-34897099
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Glucosilceramidase Tipo de estudo: Clinical_trials Limite: Adolescent / Adult / Aged / Aged80 / Humans / Middle aged Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Glucosilceramidase Tipo de estudo: Clinical_trials Limite: Adolescent / Adult / Aged / Aged80 / Humans / Middle aged Idioma: En Ano de publicação: 2022 Tipo de documento: Article